Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 12, 2014 08:00 ET | Source: Melinta Therapeutics, Inc.

Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection

- Qualified Infectious Disease Product (QIDP) Granted for Solithromycin Capsules by the FDA - - Data from Single Study Expected to be Submitted at the Same Time as the Community Acquired Bacterial...
July 29, 2014 16:05 ET | Source: Melinta Therapeutics, Inc.

Cempra, Inc. Reports Second Quarter 2014 Financial and Operating Results

CHAPEL HILL, N.C., July 29, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
July 22, 2014 16:05 ET | Source: Melinta Therapeutics, Inc.

Cempra, Inc. to Report Second Quarter 2014 Financial and Operating Results, and Host Conference Call and Webcast on July 29, 2014

CHAPEL HILL, N.C., July 22, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that it will report second quarter 2014 financial results and provide a business update after the close...
June 17, 2014 16:05 ET | Source: Melinta Therapeutics, Inc.

Cempra, Inc. to Present at JMP Securities Healthcare Conference

CHAPEL HILL, N.C., June 17, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at the JMP Securities...
May 09, 2014 19:00 ET | Source: Melinta Therapeutics, Inc.

Cempra to Present Data on Solithromycin at ECCMID Highlighting Potential New Indications, Safety and Activity Spectrum

CHAPEL HILL, N.C., May 9, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that it will present data at the European Congress of Clinical Microbiology and Infectious Diseases...
May 08, 2014 16:00 ET | Source: Melinta Therapeutics, Inc.

Cempra, Inc. to Present at Three Investor Conferences

CHAPEL HILL, N.C., May 8, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at three upcoming...
May 06, 2014 10:15 ET | Source: Melinta Therapeutics, Inc.

Cempra Presents Late-Breaker on Solithromycin's Anti NASH Effects in an Animal Model at DDW 2014

CHAPEL HILL, N.C., May 6, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc., (Nasdaq:CEMP) today announced a late-breaker presentation demonstrating that solithromycin significantly reduced ballooning...
April 29, 2014 16:00 ET | Source: Melinta Therapeutics, Inc.

Cempra, Inc. Reports First Quarter 2014 Financial and Operating Results

CHAPEL HILL, N.C., April 29, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
April 22, 2014 16:05 ET | Source: Melinta Therapeutics, Inc.

Cempra, Inc. to Report First Quarter 2014 Financial and Operating Results, and Host Conference Call and Webcast on April 29, 2014

CHAPEL HILL, N.C., April 22, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that it will report first quarter 2014 financial results and provide a business update after the close...
April 03, 2014 16:05 ET | Source: Melinta Therapeutics, Inc.

Cempra's Solithromycin Demonstrates Therapeutic Potential Beyond Anti-Bacterial Activity

CHAPEL HILL, N.C., April 3, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced the presentation of a late-breaking abstract entitled "Anti-NASH Effects of Solithromycin in NASH-HCC...